Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:ALNY) revealed 11 unusual trades. Delving into ...
Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...
In 2022, Alnylam filed a patent infringement lawsuit against Moderna, claiming it violated a newly obtained patent. The claim is over mRNA technology Moderna used in developing its COVID-19 ...
Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 19 unusual trades. Delving into the ...
Alnylam Pharmaceuticals Inc (NASDAQ ... driven by a gross to net adjustment in Portugal and large orders in partner markets in Q2. Net revenue from collaborations decreased by $370 million ...
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to $400.00. Don't Miss our Black Friday Offers ...
Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the ...
--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback